-
May 20, 2013
Takeda Pharmaceutical Co has presented positive late-stage data on a new diabetes compound called fasiglifam
Full story
-
May 02, 2013
As expected, Sanofi's earnings for the first quarter have been battered by generics, though the French drugmaker's diabetes drugs and vaccines helped soften the blow
Full story
-
May 02, 2013
UK patients with type II diabetes have gained another option to help control blood sugar levels with the launch of Sanofi's therapy Lyxumia in the country this week.
Full story
-
May 01, 2013
Novo Nordisk has posted yet another stellar set of figures, helped by strong sales of its diabetes drug Victoza
Full story
-
April 30, 2013
Drug giants Merck & Co and Pfizer have formed a new alliance to jointly develop and commercialise the latter's ertugliflozin for the treatment of type II diabetes
Full story
-
April 17, 2013
Eli Lilly has presented more promising late-stage data on its investigational long-acting diabetes drug dulaglutide
Full story
-
April 09, 2013
Clinical trials in diabetes are geared heavily to treatment rather than prevention, while they may omit population groups that could benefit substantially from better disease management, researchers from Duke University Medical Center and Duke Clinical Research Institute in the US have found.
Full story
-
April 08, 2013
Merck & Co's bid to prevent Glenmark Pharmaceuticals from selling copycat forms of its diabetes drugs Januvia and Janumet has suffered a setback in India
Full story
-
April 05, 2013
Following its acquisition of Amylin Pharmaceuticals last year, Bristol-Myers Squibb is closing the latter's headquarters in San Diego
Full story
-
April 04, 2013
Just one in five people with diabetes has their blood sugar controls under control, and, given the surging rates of the disease, the UK is facing a public health disaster if the problem is not addressed, a leading charity has warned.
Full story